TREVI THERAPEUTICS ($TRVI) posted quarterly earnings results for Q4 2025 on Tuesday, March 17th. The company reported earnings of -$0.06 per share, beating estimates of -$0.10 by $0.04. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market close: -2.77%
You can see Quiver Quantitative's $TRVI stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TREVI THERAPEUTICS Hedge Fund Activity
We have seen 103 institutional investors add shares of TREVI THERAPEUTICS stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP removed 4,765,111 shares (-55.9%) from their portfolio in Q4 2025, for an estimated $59,659,189
- MORGAN STANLEY removed 3,251,430 shares (-75.6%) from their portfolio in Q4 2025, for an estimated $40,707,903
- FMR LLC added 3,200,118 shares (+97.0%) to their portfolio in Q4 2025, for an estimated $40,065,477
- VIKING GLOBAL INVESTORS LP removed 1,930,231 shares (-37.6%) from their portfolio in Q4 2025, for an estimated $24,166,492
- EMERALD ADVISERS, LLC added 1,892,276 shares (+inf%) to their portfolio in Q4 2025, for an estimated $23,691,295
- PICTET ASSET MANAGEMENT HOLDING SA added 1,520,754 shares (+13507.0%) to their portfolio in Q4 2025, for an estimated $19,039,840
- EMERALD MUTUAL FUND ADVISERS TRUST added 1,272,373 shares (+inf%) to their portfolio in Q4 2025, for an estimated $15,930,109
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TREVI THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $TRVI in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
- Stifel issued a "Buy" rating on 12/19/2025
- Leerink Partners issued a "Outperform" rating on 11/20/2025
- Morgan Stanley issued a "Overweight" rating on 11/14/2025
- D. Boral Capital issued a "Buy" rating on 11/14/2025
- Oppenheimer issued a "Outperform" rating on 11/14/2025
To track analyst ratings and price targets for TREVI THERAPEUTICS, check out Quiver Quantitative's $TRVI forecast page.
TREVI THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $TRVI recently. We have seen 7 analysts offer price targets for $TRVI in the last 6 months, with a median target of $19.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $19.0 on 03/09/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $21.0 on 03/09/2026
- Annabel Samimy from Stifel set a target price of $18.0 on 12/19/2025
- Faisal Khurshid from Leerink Partners set a target price of $16.0 on 11/20/2025
- Kaveri Pohlman from Clear Street set a target price of $21.0 on 11/14/2025
- Leland Gershell from Oppenheimer set a target price of $24.0 on 11/14/2025
- Judah Frommer from Morgan Stanley set a target price of $19.0 on 11/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
